跳至主要内容
临床试验/CTRI/2025/11/096747
CTRI/2025/11/096747尚未招募4 期

Role of intralesional Vitamin D3 in the treatment of cutaneous warts– At a Tertiary Care Center in Central Karnataka

Department of Dermatology1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2025年12月1日最近更新:

试验速览

阶段
4 期
状态
尚未招募
入组人数
25
试验地点
1
主要终点
Proportion of patients with complete clinical clearance of all treated cutaneous warts tend of treatment.

研究概览

简要总结

THIS IS AN OPEN LABEL SINGLE ARM PHASE 4 INTERVENTIONAL STUDY CONDUCTED AT THE DEPARTMENT OF DERMATOLOGY  JJM MEDICAL COLLEGE DAVANGERE TO EVALUATE THE EFFECTIVENESS AND SAFETY OF INTRALESIONAL VITAMIN D3 FOR TREATMENT OF CUTANEOUS WARTS ELIGIBLE PATIENTS WILL RECEIVE VITAMIN D3 600000 IU EVERY 2 WEEKS FOR UPTO 6 SESSIONS THE PRIMARY ENDPOINT IS THE COMPLETE CLINICAL CLEARANCE OF TREATED WARTS AT 12 WEEKS

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
12.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • Patients with cutaneous warts and willing to give written informed consent.

排除标准

  • Pregnant and lactating women, Immunosuppresed, Allergic to vitamin D3.

结局指标

主要结局

Proportion of patients with complete clinical clearance of all treated cutaneous warts tend of treatment.

时间窗: Baseline (week 0); treatment visits (week 0,2,4,8,10) end of treatment assessment at week 12, follow up at week 24.

次要结局

  • response at 12 weeks, mean % reduction in wart number and size, time to complete clearance (weeks), recurrence rate at 24 weeks, injection pain (VAS).(Baseline (week 0); treatment visits (week 0,2,4,8,10) end of treatment assessment at week 12, follow up at week 24.)

研究者

申办方类型
Private medical college
责任方
Principal Investigator
主要研究者

K S ANISHA KABEER

JJM MEDICAL COLLEGE

研究点 (1)

Loading locations...

相似试验